Literature DB >> 291953

Specific [3H]phencyclidine binding in rat central nervous system.

S R Zukin, R S Zukin.   

Abstract

[3H]Phencyclidine (PCP) bound specifically and with high affinity (Kd = 0.15 microM at pH 7.4) to a single saturable class of binding sites in rat brain membrane preparations. Specific binding constituted approximately 70% of total binding at 0 degrees C and 33% of total binding at 37 degrees C (at 10 nM [3H]PCP). Bound [3H]PCP could be displaced by nonradioactive PCP, a series of its derivatives, and the psychotomimetic opiate N-allylnorcyclazocine (SKF 10,047) with relative potencies that closely paralleled those determined in animal behavioral tests. Muscarinic cholinergic ligands inhibited [3H]PCP binding, but only at 0.1 mM and in rank order at variance with that for binding to muscarinic sites or for pharmacological potencies. Other drugs, including opiates other than SKF 10,047, were unable to displace specifically bound [3H]PCP at 0.1 mM. [3H]PCP binding was most enriched in crude synaptosomal subcellular fractions, and was about three times higher in hippocampus (region of highest density) than in cervical spinal cord (region of lowest density). Trypsin and Pronase reduced specific [3H]PCP binding. Thus, PCP may exert its effects on the central nervous system via binding to specific brain receptor sites.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 291953      PMCID: PMC413145          DOI: 10.1073/pnas.76.10.5372

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation.

Authors:  E G GRAY; V P WHITTAKER
Journal:  J Anat       Date:  1962-01       Impact factor: 2.610

2.  Study of a new schizophrenomimetic drug; sernyl.

Authors:  E D LUBY; B D COHEN; G ROSENBAUM; J S GOTTLIEB; R KELLEY
Journal:  AMA Arch Neurol Psychiatry       Date:  1959-03

3.  Intravenous nonbarbiturate, nonnarcotic analgesics: preliminary studies. 1. Cyclohexylamines.

Authors:  V J COLLINS; C A GOROSPE; E A ROVENSTINE
Journal:  Anesth Analg       Date:  1960 May-Jun       Impact factor: 5.108

4.  Sernyl (CI-395) in clinical anaesthesia.

Authors:  M JOHNSTONE; V EVANS; S BAIGEL
Journal:  Br J Anaesth       Date:  1959-10       Impact factor: 9.166

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain.

Authors:  R C Smith; H Y Meltzer; R C Arora; J M Davis
Journal:  Biochem Pharmacol       Date:  1977-08-01       Impact factor: 5.858

7.  Identification of inosine and hypoxanthine as endogenous ligands for the brain benzodiazepine-binding sites.

Authors:  T Asano; S Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

8.  Identification of inosine and hypoxanthine as endogenous inhibitors of [3H] diazepam binding in the central nervous system.

Authors:  P Skolnick; P J Marangos; F K Goodwin; M Edwards; S Paul
Journal:  Life Sci       Date:  1978-10-09       Impact factor: 5.037

9.  Interaction of phencyclidines with the muscarinic and opiate receptors in the central nervous system.

Authors:  J P Vincent; D Cavey; J M Kamenka; P Geneste; M Lazdunski
Journal:  Brain Res       Date:  1978-08-18       Impact factor: 3.252

10.  Some structure activity relationships of phencyclidine derivatives as anticholinergic agents in vitro and in vivo.

Authors:  S Maayani; H Weinstein
Journal:  Prog Clin Biol Res       Date:  1979
View more
  60 in total

1.  Modulation of MK-801 response by dopaminergic agents in mice.

Authors:  A Verma; S K Kulkarni
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Authors:  Bita Moghaddam; Daniel Javitt
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Potentiation of disruptive effects of dextromethorphan by naloxone on fixed-interval performance in rats.

Authors:  T Taşkin
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Phencyclidine is a negative allosteric modulator of signal transduction at two subclasses of excitatory amino acid receptors.

Authors:  J T Wroblewski; F Nicoletti; E Fadda; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

5.  A rapid method for evaluating the behavioral effects of phencyclidine-like dissociative anesthetics in mice.

Authors:  G E Evoniuk; R P Hertzman; P Skolnick
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  NMDA receptor and schizophrenia: a brief history.

Authors:  Joseph T Coyle
Journal:  Schizophr Bull       Date:  2012-09       Impact factor: 9.306

7.  Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli.

Authors:  J C Winter; J R Eckler; R A Rabin
Journal:  Psychopharmacology (Berl)       Date:  2003-11-04       Impact factor: 4.530

8.  Effects of phencyclidine, haloperidol, and naloxone on fixed-interval performance in rats.

Authors:  G C Wagner; D B Masters; A Tomie
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine.

Authors:  B L Largent; A L Gundlach; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  Phencyclidine ("angel dust") analogs and sigma opiate benzomorphans cause cerebral arterial spasm.

Authors:  B T Altura; R Quirion; C B Pert; B M Altura
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.